在固体瘤中Sacituzumab govitecan的有效性和安全性:系统性审查和元分析
Yaping Zhang1, Jian Chen2, Xiaoyan Wang1
1Department of Oncology, Affliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
Frontiers in oncology
|July 8, 2025
概括
萨西图祖马布 (Sacituzumab) 改善了固体瘤的整体存活率和无进展存活率,但增加了中性衰竭和腹的风险. 它在乳腺癌和泌尿器癌中显示出更大的益处.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 萨西图祖马布 (Sacituzumab) govitecan (SG) 是一种抗体-药物结合体,向热囊细胞表面抗原2和SN-38.
- 在固体瘤中,SG显示有前途,但疗效和安全性数据需要全面评估.
研究的目的:
- 在固体瘤中系统地审查和元分析SG的治疗疗效和安全性.
- 将SG的结果与化疗进行比较,并评估不良事件.
主要方法:
- 在PubMed,Embase和Cochrane图书馆系统搜索RCT和单臂研究,截至2025年2月14日.
- 主要结局:整体应答率 (ORR),疾病控制率 (DCR),无进展生存率 (PFS),整体生存率 (OS) 和不良事件 (AE).
主要成果:
- 与化疗相比,SG在五个RCT中显著改善了OS,PFS和DCR.
- 与SG一起观察到的中性减肥,白血减肥,腹和贫血的发病率增加.
- 单臂元分析显示,合并ORR为21%,DCR为62%,中位数OS为10.29个月.
结论:
- 在固体瘤的化疗中,SG提供了优越的OS,PFS和DCR,尽管AEs增加了.
- 亚组分析表明,乳腺癌和泌尿器癌的临床益处更大.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
